SER-601 (COR-167) is a drug which acts as a potent and selective cannabinoid CB2 receptor agonist, based on a quinolone-3-carboxylic acid core structure, with 190 times selectivity for CB2 over the related CB1 receptor. It has analgesic effects in animal studies, as well as neuroprotective effects,[1] but without a "cannabis high" due to its low affinity for CB1.[2] A number of related compounds are known, almost all of which have high selectivity for CB2.[3]
Clinical data | |
---|---|
Routes of administration | Oral |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H38N2O2 |
Molar mass | 434.624 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
See also
editReferences
edit- ^ Contartese A, Valoti M, Corelli F, Pasquini S, Mugnaini C, Pessina F, et al. (December 2012). "A novel CB2 agonist, COR167, potently protects rat brain cortical slices against OGD and reperfusion injury". Pharmacological Research. 66 (6): 555–563. doi:10.1016/j.phrs.2012.08.003. PMID 23036353.
- ^ Pasquini S, Botta L, Semeraro T, Mugnaini C, Ligresti A, Palazzo E, et al. (August 2008). "Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo". Journal of Medicinal Chemistry. 51 (16): 5075–5084. doi:10.1021/jm800552f. PMID 18680276.
- ^ Pasquini S, Ligresti A, Mugnaini C, Semeraro T, Cicione L, De Rosa M, et al. (August 2010). "Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands". Journal of Medicinal Chemistry. 53 (16): 5915–5928. doi:10.1021/jm100123x. PMID 20718492.